Emergent BioSolutions/EBS

$2.06

-5.93%
-
1D1W1MYTD1YMAX

About Emergent BioSolutions

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

Ticker

EBS

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Joseph Papa

Employees

1,600

Headquarters

Gaithersburg, United States

EBS Metrics

BasicAdvanced
$107.54M
Market cap
-
P/E ratio
-$14.75
EPS
1.22
Beta
-
Dividend rate
$107.54M
1.21611
$12.87
$1.42
2.99M
1.043
0.538
68.766
132.481
-1.96%
-30.48%
-74.67%
-48.92%
0.102
0.166
1.3
-5.86%
-234.02%
-12.3%

What the Analysts think about EBS

Analyst Ratings

Majority rating from 2 analysts.
Hold

Price Targets

Average projection from 1 analyst.
142.72% upside
High $5.00
Low $5.00
$2.06
Current price
$5.00
Average price target

EBS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-17.89% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$276.6M
2.26%
Net income
$-49.5M
-81.21%
Profit margin
-17.89%
-81.63%

EBS Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 305.26%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$3.17
-$1.06
-$0.48
-$0.77
-
Expected
-$1.24
-$0.49
-$0.22
-$0.19
-$0.83
Surprise
155.65%
117.81%
114.93%
305.26%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Emergent BioSolutions stock?

Emergent BioSolutions (EBS) has a market cap of $107.54M as of April 14, 2024.

What is the P/E ratio for Emergent BioSolutions stock?

The price to earnings (P/E) ratio for Emergent BioSolutions (EBS) stock is 0 as of April 14, 2024.

Does Emergent BioSolutions stock pay dividends?

No, Emergent BioSolutions (EBS) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Emergent BioSolutions dividend payment date?

Emergent BioSolutions (EBS) stock does not pay dividends to its shareholders.

What is the beta indicator for Emergent BioSolutions?

Emergent BioSolutions (EBS) has a beta rating of 1.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Emergent BioSolutions stock price target?

The target price for Emergent BioSolutions (EBS) stock is $5, which is 142.72% above the current price of $2.06. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Emergent BioSolutions stock

Buy or sell Emergent BioSolutions stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing